Last reviewed · How we verify
Methotrexate-LDE phase 1
At a glance
| Generic name | Methotrexate-LDE phase 1 |
|---|---|
| Also known as | MTX-LDE phase 1 |
| Sponsor | University of Sao Paulo General Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methotrexate-LDE phase 1 CI brief — competitive landscape report
- Methotrexate-LDE phase 1 updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI